Drug targeting

Details Drug targeting Drug targeting

1998-02-13

2010-11-09

Dentz, Bernard (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S681000, C514S690000, C552S297000, C552S299000, C552S307000, C552S581000

Reexamination Certificate

active

07829555

ABSTRACT:
The invention provides a method of targeting a drug to areas of hypoxic and/or ischemic tissue within the body in which the desired drug species is linked to a non-cytotoxic bioreductive carrier. Also provided by the invention are novel bioreductive conjugates comprising a non-cytotoxic bioreductive moiety with linked-thereto at least one therapeutic agent. The compounds of the invention are particularly suitable for the treatment of rheumatoid arthritis and other arthritic conditions, diabetes, atherosclerosis, stroke, sepsis, Alzheimer's disease and other neurological disorders, cancer, kidney disease, digestive diseases, liver disease, chronic periodontitis or ischemia following tissue transplantation.

REFERENCES:
patent: 5086068 (1992-02-01), Raleigh et al.
patent: 5387692 (1995-02-01), Riley et al.
patent: 5652255 (1997-07-01), Adams et al.
patent: 2 131 020 (1984-06-01), None
patent: WO 93/00900 (1993-01-01), None
patent: WO 93/00904 (1993-01-01), None
patent: WO 93/05054 (1993-03-01), None
patent: WO 94/06797 (1994-03-01), None
patent: WO 94/06798 (1994-03-01), None
patent: WO 94/22483 (1994-10-01), None
patent: WO 97/23456 (1997-07-01), None
Oellinger et al, “Study on the redox properties of naphthazarin (5,8-dihydroxy-1,4-naphthoquinone) and its glutathionyl conjugate in biological reactions: one- and two-electron enzymic reduction”,Chemical Abstracts, vol. 112, No. 11, Mar. 12, 1990, Columbus, Ohio, US; andArch. Biochem. Biophys.(1989).
Firestone et al, “Nitro heterocycle reduction as a paradigm for intramolecular catalysis of drug delivery to hypoxic cells”,J. Med. Chem, (1991), 34(9).
Chikhale et al, “Tumor targeted prodrugs: Redox-activation of conformationally constrained, bioreductive melphalan prodrugs”,Eighty-Eighth Annual Meeting of the American Association for Cancer Research, San Diego, California, USA, Apr. 12-16, 1997.Proceedings of the American Association for Cancer Research Annual Meeting(38 (0). 1997. 432-433.
Mehta et al, “Potential bioreductively activated hypoxia probes and post-irradiation radiosensitizers related to NITP”,Anti-Cancer Drug Des.(1995), 10(3), 227-41.
Hodgkiss et al, “Pharmacokinetics and binding of the bioreductive probe for hypoxia, NITP: effect of route of administration”,Br. J. Cancer, vol. 72, 1995, pp. 1462-1468.
Berglund, “Bioreductive Heterosubstituted Quinone Antitumor Drug Delivery Agents”,Database Dissabs, 1987.
Edmonds et al, “Hypoxia and the Rheumatoid Joint: Immunological and Therapeutic Implications”, Scand. J. Rheumatol. 24(Suppl 101):163-168 (1995).
Notification of Transmittal of The International Preliminary Examination Report issued in connection with PCT/GB98/00461 dated May 18, 1999.
The Merck Index, “Glutathione”, p. 703, item 4369 (1989).
Japanese Official Action.
Ollinger et al, “Study of the Redox Properties of Napthazarin (5,8-Dihydroxy-1,4-naphthoquinone) and its Glutathionyl Conjugate in Biological Reactions: One- and Two-Electron Enzymatic Reduction”, Archives of Biochemistry and Biophysics 275(2):514-530 (1989).
Firestone et al, “Nitroheterocycle Reduction as a Paradigm for Intramolecular Catalysis of Drug Delivery to Hypoxi Cells”, J. Med. Chem. 34(9):2933-2935 (1991).
Cotterill et al, “Cyclopropamitosenes, Novel Bioreductive Anticancer Agents. Synthesis, Electrochemistry, and Biological Activity of 7-Substituted Cyclopropamitosenes and Related Indolequinones”, J. Med. Chem. 37(22):3834-3843 (1994).

Affiliated with

Also associated with

Rating

Drug targeting does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Drug targeting, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug targeting will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4178098